Page 79 - MemoriaCIBER-2017ENG
P. 79
Scienti c Production
PUBLICATIONS
No of publications in 2017
Collaboration work IntraCIBER 165
611 Q1 160
TOTAL
D1
325
Evolution of the publications
700
600
500
400
300
200
100
InterCIBER
97
2010 2011
2012 2013
2014 2015
2016 2017
Most relevant publications of the CIBEREHD in 2017 by impact factor
Publication Impact Factor
Sandborn W J , Su C , Sands B E , D'Haens G R , Vermeire S , Schreiber S et al Tofacitinib
as induction and maintenance therapy for ulcerative colitis New England Journal of 72,4060 Medicine 2017;376(18):1723-1736
Lanas A , Chan F K L Peptic ulcer disease The Lancet 2017
47,8310
El-Khoueiry A B , Sangro B , Yau T , Crocenzi T S , Kudo M , Hsu C et al Nivolumab in
patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non- 47,8310 comparative, phase 1/2 dose escalation and expansion trial The Lancet 2017
Bruix J , Qin S , Merle P , Granito A , Huang Y -H , Bodoky G et al Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial The Lancet 2017
47,8310
523
581
572
611
626
621
632
607
